Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (Symbol: NTRA) is a leading diagnostic and research company based in San Carlos, CA, driven by a commitment to advance the science and application of prenatal testing. In the information age, medical diagnostics have lagged behind in adopting new technologies, but Natera is changing that narrative. The company specializes in preconception and prenatal genetic testing services, providing couples with crucial information throughout the pregnancy journey.
Natera offers a comprehensive range of tests, including Preimplantation Genetic Diagnosis (PGD) for IVF and Non-Invasive Prenatal Testing (NIPT). Their Panorama NIPT is particularly notable for its ability to screen for chromosomal abnormalities in a fetus, even in twin pregnancies, typically through a simple blood draw from the mother. Another significant product is the Horizon Carrier Screening (HCS), which determines carrier status for numerous severe genetic diseases that could be passed on to offspring.
The company's innovative approach leverages advances from the Human Genome Project and is powered by proprietary bioinformatics algorithms. This technology enables highly accurate genetic testing results. Natera's portfolio also includes the Signatera Molecular Residual Disease (MRD) Test, designed to detect circulating tumor DNA in cancer patients, helping to assess molecular residual disease and monitor recurrence. Additionally, the Prospera test assesses organ transplant rejection.
Through its pioneering genetic testing services and experienced genetic counseling, Natera provides valuable insights that help in informed decision-making for pregnancies and medical conditions. The company continues to make significant strides in the field of medical diagnostics, driven by a passion for innovation and excellence.
Natera (NASDAQ: NTRA), a leading provider of cell-free DNA and genetic testing services, has announced its upcoming fourth quarter and full year 2024 financial results release. The company will disclose its results after market close on February 27, 2025, followed by a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET).
Interested parties can access the conference call through domestic (1-888-770-7321) or international (1-929-201-7101) dial-in numbers using Conference ID 7684785. A webcast will be available at the provided link, with a replay accessible later at investor.natera.com.
Natera (NASDAQ: NTRA) announced significant updates to the National Comprehensive Cancer Network (NCCN) Guidelines regarding circulating tumor DNA (ctDNA) testing. The NCCN has now included ctDNA as a high risk factor for recurrence in colon and rectal cancer guidelines, marking the first formal recognition of ctDNA's prognostic value.
For Merkel Cell Carcinoma (MCC), the guidelines now positively recommend ctDNA monitoring for surveillance, suggesting tests every 3 months. This recommendation cites Natera's Signatera study data, which showed 95% detection at enrollment and 20x higher recurrence risk in persistently positive patients.
MCC, affecting approximately 3,000 patients annually (mostly elderly), has a 40% recurrence rate within 5 years. The inclusion of ctDNA testing in these guidelines represents a significant step toward more personalized cancer care.
Natera (NASDAQ: NTRA) has secured national commercial coverage for its cfDNA Fetal RhD noninvasive prenatal test from one of the largest U.S. payors. The coverage, effective January 2025, will be available when pregnancies are at risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if amniocentesis is declined or not recommended.
The test, which can be performed as early as nine weeks into pregnancy, determines fetal RhD status from maternal blood samples. This is particularly significant as up to 15% of pregnant patients are RhD-negative. When a mother is RhD-negative and the fetus is RhD-positive, there's a risk of antibody development leading to hemolytic disease of the fetus and newborn.
The test is part of Natera's women's health product suite, which includes Panorama, the most ordered NIPT in the United States.
Natera (NTRA) announced significant results from two clinical trials in colorectal cancer (CRC). The Phase III CALGB/SWOG 80702 study, involving ~1,000 patients, demonstrated that Signatera-positive patients treated with both chemotherapy and celecoxib showed a 40% improvement in overall survival compared to chemotherapy alone.
Key findings revealed that adding celecoxib to standard chemotherapy significantly improved disease-free survival (DFS) in Signatera-positive patients, with a three-year DFS of 44.1% versus 26.6%. The study also confirmed Signatera's effectiveness in predicting recurrence.
Additionally, the ALTAIR clinical trial, studying 243 Signatera-positive patients, showed promising results for stage IV CRC patients treated with Trifluridine/Tipiracil (FTD/TPI). These patients demonstrated a median DFS of 9.76 months compared to 3.96 months in the placebo group, marking a significant advancement in personalized medicine for CRC treatment.
Natera Inc (NASDAQ: NTRA) announced multiple studies to be presented at the 2025 ASCO GI Symposium in San Francisco. Key highlights include data from the BESPOKE CRC study, the largest prospective MRD study in the U.S., which demonstrated Signatera's effectiveness as a prognostic and predictive biomarker in colorectal cancer patients.
The study showed that Signatera-positive patients had significantly inferior outcomes in both stage II (HR=10.4) and stage III patients (HR=10.1). The 24-month disease-free survival rates were 91.7% for Signatera-negative and 41.4% for Signatera-positive patients.
Additionally, Natera will present initial results from their novel tissue-free MRD detection test, showing high sensitivity and specificity, and early cancer detection data with 95% sensitivity and 91% specificity in colorectal cancer detection. The symposium will feature multiple presentations, including a late-breaking oral presentation on the CALGB/SWOG 80702 study.
Natera CEO Steve Chapman has received two significant recognitions in 2024: being named one of the top healthcare technology CEOs by Healthcare Technology Report and 'BioTechnology Innovator of the Year' by BioTech Breakthrough Awards. During his 15-year tenure at Natera, including serving as CEO since 2019, the company has published over 250 peer-reviewed papers and launched 20 products that have transformed patient care.
Under Chapman's leadership, Natera has developed key products including the Signatera™ oncology test, Prospera™ transplant assessment test, and Panorama™ non-invasive prenatal test. The Healthcare Technology Report's annual program recognizes the top 50 CEOs in biotechnology and life sciences, while the BioTech Breakthrough Awards received nominations from over 14 countries globally.
Natera (NASDAQ: NTRA) announced updates to its oncology innovation roadmap at the 43rd Annual J.P. Morgan Healthcare Conference. The company introduced three key developments:
1. A new version of Signatera leveraging whole genome sequencing (WGS), now available for research and clinical use, detecting down to low single-digit parts per million.
2. A novel tissue-free molecular residual disease (MRD) capability, with first launch expected in mid-2025 for colorectal cancer (CRC), utilizing methylation-based technologies.
3. Preliminary data for their Early Cancer Detection (ECD) assay, showing 92% detection of stage 1 CRC and 95% detection overall, with 91% specificity. The company plans to present additional data from the PROCEED-CRC cohort later this year, followed by an FDA-grade validation study if results are positive.
Natera (NTRA) has released preliminary unaudited results for Q4 and full-year 2024, showing significant growth across key metrics. The company expects Q4 2024 revenues of approximately $472 million, up 52% from Q4 2023, and full-year 2024 revenues of approximately $1.7 billion, representing a 56% increase from 2023.
Test volumes showed strong growth, with 792,800 tests processed in Q4 2024 (26.5% increase) and 3,064,600 tests for full-year 2024 (22.8% increase). Notably, oncology testing saw substantial growth, with 150,800 oncology tests in Q4 2024, marking a 54.7% increase. The company achieved positive cash inflows of $45.8 million in Q4 2024 and $86.3 million for full-year 2024, compared to previous year's cash outflows.
Natera (NASDAQ: NTRA), a leading cell-free DNA testing company, has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team will deliver a presentation and conduct a Q&A session with investors on Wednesday, January 15, 2025, at 9:00 a.m. PT (12:00 p.m. ET).
Interested parties can access a live webcast of the event through the investor relations section of Natera's website at investor.natera.com. A recording of the presentation will be made available shortly after the conference concludes.
Natera (NASDAQ: NTRA) has expanded its patent infringement lawsuit against NeoGenomics by adding U.S. Patent No. 11,319,596 to the case. The District Court for the Middle District of North Carolina granted Natera's request on December 10, 2024. The amended complaint now includes both the '596 and previously asserted '454 patents, claiming infringement by NeoGenomics' modified RaDaR® test for molecular residual disease. This legal action follows earlier court decisions in December 2023 and September 2024 that resulted in preliminary and permanent injunctions against NeoGenomics' previous version of the RaDaR® test. Natera is pursuing full remedies, including injunctive relief, against NeoGenomics' current RaDaR® test offering.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
What does Natera, Inc. specialize in?
Where is Natera, Inc. headquartered?
What is the Panorama Non-Invasive Prenatal Test (NIPT)?
What is the Horizon Carrier Screening (HCS)?
What is the Signatera Molecular Residual Disease (MRD) Test?
What is the purpose of the Prospera test?
How has Natera advanced genetic testing?
Does Natera offer genetic counseling services?
What industries does Natera serve?
What makes Natera's tests unique?
